PERU is grappling with a rare disease called Guillain-Barré Syndrome (GBS), a rare autoimmune disorder that targets the nerves, resulting in muscle weakness, and in severe instances, paralysis or even death.
Since June of this year, Peru has reported a total of 182 cases, with four unfortunate fatalities.
The decision to declare a health emergency came after a request made by Health Minister César Vásquez, who expressed concerns over the unusual rise in cases, speculating that it could be linked to a lack of antibodies known as immunoglobulin.
In an official statement released on Saturday, the Peruvian government revealed that 103 cases had already been reported as of June 23, with the monthly average remaining below 20 cases nationwide.
This figure is lower than the numbers seen in previous years before the 2019 outbreak.
To combat the outbreak and improve patient care, President Dina Boluarte‘s decree has allocated approximately US$3.27 million in funding.
These funds will be utilized to enhance healthcare services, strengthen disease surveillance and control measures, and provide detailed reports to both the population and healthcare personnel.
GBS typically begins with symptoms such as weakness and tingling in the hands and feet.
The damage caused by the syndrome interrupts the transmission of touch sensations from the nerves to the spinal cord and brain, resulting in numbness.
Furthermore, the affected nerves are unable to transmit signals back to the body, leading to muscle weakness.
The progression of GBS can potentially lead to paralysis.
The exact cause of the disease remains unknown.
However, it is frequently reported that two-thirds of patients experience preceding infections within the six weeks prior to GBS onset, including respiratory or gastrointestinal infections, zika virus, or even COVID-19.
While there is currently no known cure for Guillain-Barré Syndrome, treatments are available to manage symptoms, reduce their severity, and shorten the duration of the illness.
The recovery period varies, with most patients taking two to three weeks to recuperate fully.
However, some cases have shown recovery taking several years.
It is important to note that GBS can leave permanent nerve damage in certain individuals, leading to chronic weakness, numbness, or fatigue.
The Peruvian government’s decisive actions and allocation of resources aim to effectively address the ongoing outbreak, ensure comprehensive patient care, and minimize the impact of Guillain-Barré Syndrome on the population.
